effera
(2)
Helaina
Helaina is a New York-based biotechnology company using precision fermentation to produce human-equivalent bioactive proteins. Its first commercial product, effera, is a human-identical lactoferrin made in yeast that matches the amino acid sequence of the protein found in mother's milk. Founded in 2019 by food scientist Laura Katz, Helaina sells effera as a B2B ingredient to consumer wellness and supplement brands, targeting women's health, gut health, active nutrition and healthy aging. The company has raised roughly $84 million in equity funding, including a $45 million Series B in 2024.
Laura Katz
Laura Katz is the founder and CEO of Helaina, a New York biotech company that uses precision fermentation to produce human-identical bioactive proteins. Its first product, effera, is the world's first commercially available human lactoferrin made through yeast fermentation. A food scientist by training and once NYU's youngest adjunct professor in Food Science, Katz started the company in 2019 from her Lower East Side kitchen after hearing a podcast about the black market for breast milk. She has raised more than $80 million to move Helaina from research into a commercial ingredient business.